Revvity, Inc. (RVTY) Up 11.9% — Should I Acquire Shares Here?
Revvity, Inc. (RVTY) is surging this Tuesday, last trading at $169.61 on the NYSE. That is an $18.01 gain from the prior close of $151.60 and one of the sharpest single-session advances the stock has posted this year. The rally carries RVTY past its previous 52-week high of $169.06, a level set only days ago on October 28, 2026. The stock is now trading in fresh 52-week-high territory and extending a run that was already underway heading into the print.
Volume stands at roughly 1.57 million shares with the session still open, compared to a 90-day average of about 1.77 million. That puts turnover at nearly 89% of a typical full day's activity well before the closing bell. The pace keeps today on track to finish well above normal levels.
Why Revvity, Inc. Price is Moving Higher
The catalyst is squarely company-specific. Revvity reported Q3 2026 results on November 3, and beat estimates on both lines while lifting its full-year outlook. Adjusted EPS came in at $1.38 against a $1.29 consensus estimate, up from $1.18 a year earlier. Revenue reached $728.9 million versus an analyst estimate of $694.7 million, a 4.3% increase from $698.9 million in the prior-year quarter. The underlying picture is even stronger. On a pro forma basis that excludes the China Immunodiagnostics business, revenue was $709.6 million, up 7.4% year over year. That figure shows the core portfolio accelerating well beyond what the headline number suggests.
Life Sciences was the standout segment, delivering 9% pro forma organic revenue growth. Profitability expanded alongside the top line. Adjusted operating margin for continuing operations climbed to 29.4% from 26.0%, a 340-basis-point improvement that shows Revvity converting growth into earnings efficiently. GAAP results confirmed the trend. Reported EPS rose to $0.56 from $0.41, and GAAP operating margin improved to 13.1% from 11.7%.
Management then raised the bar for the rest of 2026. It lifted its pro forma adjusted EPS outlook to $5.40–$5.45 from the $5.30–$5.40 range set after Q2 results on August 4. The company also pinned revenue at about $2.86 billion, the top of its prior $2.83 billion–$2.86 billion range. Revvity's move stands well apart from its group peers. Danaher Corporation (DHR) gained a more modest 1.78% today, while Merck & Co., Inc. (MRK) slipped 2.43%. That gap shows investors are rewarding Revvity's execution specifically, not riding a broad Health Care tailwind.
What is the Revvity, Inc. Rating - Should I Buy?
Weiss Ratings assigns RVTY a C rating. Current recommendation is Hold. That rating balances a strong balance sheet and powerful recent price performance against operating metrics that are only now beginning to turn. Today's results suggest those operating metrics have room to catch up.
Revvity's strengths start with its rating of Excellent on the Solvency Index. For a company investing across reagents, instruments, software, and diagnostics, that financial flexibility lets management fund growth initiatives and absorb portfolio reshaping like the China Immunodiagnostics exit without straining the balance sheet. The Excellent rating on the Total Return Index reflects what shareholders have actually experienced. The stock has been climbing steadily enough to set a 52-week high on October 28, and today's earnings-driven surge pushed it beyond that level.
Where the picture becomes more nuanced is on the operating side. The Fair rating on the Growth Index reflects trailing revenue growth of just 1.31%, a muted figure weighed down by the businesses Revvity is moving away from. The 7.4% pro forma growth and 9% organic Life Sciences expansion reported today point to a stronger trajectory than the trailing numbers capture. Efficiency is also rated Fair. A 3.21% ROE and 8.15% profit margin remain modest for a life sciences tools company, which helps explain the 72.14 forward P/E. The market is paying today for margin gains it expects ahead. The 340-basis-point jump in adjusted operating margin is exactly the kind of progress that could lift this dimension over time. The Fair Volatility Index fits a stock capable of an 11.88% one-day move on an earnings beat and guidance raise. The Weak Dividend Index reflects a 0.18% yield, which makes clear this is a capital-appreciation story rather than an income play.
Within the Health Care sector, Revvity sits alongside Danaher Corporation (DHR, C), its closest life sciences tools comparison, and Gilead Sciences, Inc. (GILD, C). It trails Regeneron Pharmaceuticals, Inc. (REGN, C+), which holds a slightly stronger risk/reward profile in Weiss's framework.
About Revvity, Inc.
Revvity, Inc. (RVTY) is a Health Care company that provides tools, technologies, and services that support research, drug discovery, and diagnostics. Headquartered in Waltham, Massachusetts, the company adopted the Revvity name in 2023 after the former PerkinElmer divested its analytical and enterprise services operations. That reshaping left a sharper focus on higher-growth life sciences and diagnostics markets. The company operates through two segments, Life Sciences and Diagnostics, and serves pharmaceutical and biotech companies, academic and government research institutions, hospitals, and clinical laboratories worldwide.
The Life Sciences segment supplies a broad portfolio of research reagents, including BioLegend antibodies and Horizon Discovery gene-editing and cell-engineering tools. It pairs those consumables with instruments such as the Opera Phenix high-content screening system and EnVision multimode plate readers. Its Signals software platform, including Signals Notebook, gives scientists data management and analytics capabilities that tie the workflow together. The Diagnostics segment is a global leader in newborn screening and also offers immunodiagnostics through its EUROIMMUN business, along with reproductive health and specialty testing solutions.
Revvity's competitive advantage rests on the recurring nature of much of its revenue. Reagents, consumables, software subscriptions, and diagnostic assays generate repeat purchases once its platforms are embedded in customer labs and screening programs. Its long-standing position in newborn screening gives it deep relationships with public health laboratories. Its combination of biology-focused reagents, screening instruments, and scientific software lets it serve customers across the drug discovery process, from target identification through translational research.
Investor Outlook
Revvity, Inc. (RVTY) carries a Weiss Rating of C (Hold), but its Q3 beat, 9% organic Life Sciences growth, and raised $5.40–$5.45 EPS outlook give investors a stronger fundamental case than the trailing metrics suggest. The key items to watch are whether Q4 results deliver on the roughly $2.86 billion revenue target and whether the expanding adjusted operating margin carries into 2027 guidance. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--